STIFEL 2026: Oruka's IL-23p19 is showing strong efficacy in phase 2 studies compared to existing products and could be dosed as little as once or twice a year - a key update will read next month

0:00-11:13

CEO Lawrence Klein describes the data that has been seen so far (clearance in the 60% range at 16 weeks) and previews with upcoming 52 week data that will be coming in December. Plus, how the company is thinking about phase 3 design, and other assets in the pipeline.

B-

BiotechTV - News

@biotechtvnews

#showingstrongefficacy #studiescompared #existingproducts #lifesciences

The Nile